Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry").
Zeynep Belce ErtonRebecca K LeafDanieli Castro de Oliveira AndradeAnn E ClarkeMaria G G TektonidouVittorio PengoSavinio SciasciaAmaia UgarteH Michael BelmontMaria GerosaPaul R FortinChary Lopez-PedreraTatsuya AtsumiZhouli ZhangHannah CohenGuilherme Ribeiro Ramires de JésusDavid Ware BranchDenis WahlLaura AndreoliEsther Rodríguez-AlmarazMichelle A PetriGiuseppe BarilaroYu ZuoBahar Artım EsenRohan WillisRosana Maris QuintanaMargarete Bg VendraminiMegan W BarberMaria Laura BertolacciniRobert RoubeyDoruk ErkanPublished in: Lupus (2022)
In our international cohort, 14% of aPL-positive patients without other SAIDx were reported to receive IS; the indication was at least one of the selected microvascular and/or non-thrombotic aPL-related manifestations in half. Thrombocytopenia was the most frequent among those selected aPL-related manifestations; however, approximately one-third received IS specifically for that indication. Diffuse alveolar hemorrhage was frequently treated with IS followed by AIHA and aPL-N. Systematic controlled studies are urgently needed to better define the role of IS in APS.